

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and is not intended to and does not constitute, or form part of, any offer to purchase or subscribe for or an invitation to purchase or subscribe for any securities of the Offeror or the Company or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law.



Meditech Global Group Limited

*(Incorporated in the British Virgin Islands
with limited liability)*

GOLDEN MEDITECH HOLDINGS LIMITED

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00801)

JOINT ANNOUNCEMENT

**PROPOSAL FOR THE PRIVATISATION OF
GOLDEN MEDITECH HOLDINGS LIMITED BY THE OFFEROR
BY WAY OF A SCHEME OF ARRANGEMENT
(UNDER SECTION 86 OF THE COMPANIES LAW)**

COMPLETION OF 2ND TRANCHE SUBSCRIPTION

Financial Adviser to the Offeror

AMASSE CAPITAL
寶 積 資 本

Independent Financial Adviser to the Company



SOMERLEY CAPITAL LIMITED

Reference is made to (i) the composite scheme document dated 21 August 2020 (the “**Scheme Document**”) issued jointly by Golden Meditech Holdings Limited (the “**Company**”) and Meditech Global Group Limited (the “**Offeror**”) in relation to, among other things, the proposed privatisation of the Company by way of a scheme of arrangement (the “**Scheme**”); (ii) the clarification announcement dated 24 August 2020 issued jointly by the Company and the Offeror in relation to the forms of proxy for use at the Court Meeting and the General Meeting; and (iii) the results announcement dated 16 September 2020 (the “**Results Announcement**”) issued jointly by the Company and the Offeror in relation to the results of the Court Meeting and the General Meeting. Capitalised terms used herein shall have the same meanings as those defined in the Scheme Document unless the context requires otherwise.

COMPLETION OF 2ND TRANCHE SUBSCRIPTION

As set out in the Results Announcement, the Court Meeting and the General Meeting were held on Wednesday, 16 September 2020, during which all relevant resolutions in relation to the Proposal and the Scheme were duly approved by the Scheme Shareholders or Shareholders (as the case may be) in accordance with the relevant requirements under the Takeovers Code and the Companies Law of the Cayman Islands.

The Board and the Offeror would like to announce that completion of the 2nd Tranche Subscription took place on 18 September 2020 pursuant to the terms of the Subscription Agreement.

As at the date of this joint announcement and immediately following completion of the 2nd Tranche Subscription, the shareholding percentage owned by each of the Subscribers in the Offeror remains unchanged, and the Offeror was owned as to approximately 67.27% by Bio Garden Inc., 12.73% by China In Shine Investment Limited, 10.91% by Asia Pacific MedTech (BVI) Limited and 9.09% by Famous Sino Limited.

The table below sets out the shareholding structure of the Offeror (i) immediately following the 1st Tranche Completion Date; and (ii) immediately following the 2nd Tranche Completion Date:

Shareholders	Immediately following the 1st Tranche Completion Date		Immediately following the 2nd Tranche Completion Date	
	<i>Number of shares</i>	<i>%</i>	<i>Number of shares</i>	<i>%</i>
Bio Garden Inc.	37	67.27	6,727	67.27
China In Shine Investment Limited	7	12.73	1,273	12.73
Asia Pacific MedTech (BVI) Limited	6	10.91	1,091	10.91
Famous Sino Limited	<u>5</u>	<u>9.09</u>	<u>909</u>	<u>9.09</u>
	<u>55</u>	<u>100.00</u>	<u>10,000</u>	<u>100.00</u>

The cash proceeds received from the 1st Tranche Subscription and the 2nd Tranche Subscription will be used to finance the Proposal.

WARNING: Shareholders and potential investors should be aware that the implementation of the Proposal and the Scheme is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal may or may not be implemented and the Scheme may or may not become effective. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

By order of the board of
Meditech Global Group Limited
KAM Yuen
Sole Director

By order of the board of
Golden Meditech Holdings Limited
Feng Wen
Chairman

Hong Kong, 18 September 2020

As at the date of this joint announcement, the Board comprises five Directors. The executive Directors are Mr. Feng Wen (Chairman) and Mr. Leong Kim Chuan (Chief Executive); and the independent non-executive Directors are Mr. Gao Yue, Mr. Poon Tsz Hang and Mr. Daniel Foa.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Offeror or any of the Offeror Concert Parties) and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Offeror or any of the Offeror Concert Parties) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, (i) the sole director of the Offeror is Mr. Kam; (ii) the sole director of Bio Garden Inc. is Mr. Kam; (iii) the sole director of China In Shine Investment Limited is Ms. Fung Chit; (iv) the sole director of Asia Pacific MedTech (BVI) Limited is Ms. Gu Nana; and (v) the sole director of Famous Sino Limited is Mr. Wu Guangze.

Mr. Kam (in his capacity as the sole director of the Offeror) accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

Mr. Kam (in his capacity as the sole director of Bio Garden Inc.), Ms. Fung Chit (in her capacity as the sole director of China In Shine Investment Limited), Ms. Gu Nana (in her capacity as the sole director of Asia Pacific MedTech (BVI) Limited) and Mr. Wu Guangze (in his capacity as the sole director of Famous Sino Limited) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of her/his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.